2 active not recruiting, 2 unknown, 1 completed, 1 recruiting. 3 Phase 1, 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 2 | 2 | Unknown 2 |
Follow FutureChem: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer [177-Lu]Ludotadipep, Best supportive care/standard of care (BSC/SOC) alone - Prostate Cancer, mCRPC | Phase 3 | Recruiting | FutureChem | 114 | 2026-01-26 | 2026-10-01 |
| [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer [F-18]Florastamin - High Risk Prostate Carcinoma | Phase 3 | Active not recruiting | FutureChem | 138 | 2023-05-08 | 2025-03-12 |
| [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 [177Lu]Ludotadipep - Metastatic Castration-resistant Prostate Cancer, mCRPC | Phase 2 | Unknown | FutureChem | 20 | 2022-10-30 | 2024-04-29 |
| [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application [177Lu]Ludotadipep 3.7 GBq - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Unknown | FutureChem | 26 | 2022-09-01 | 2024-04-29 |
| Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis [F-18]Florastamin - High Risk Prostate Carcinoma | Phase 3 | Active not recruiting | FutureChem | 398 | 2021-04-28 | 2025-03-12 |
| [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer [18F]FLOR (FC303) Injection - Metastatic Prostate Cancer | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2021-02-01 | 2024-01-16 |
| [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. [177Lu]Ludotadipep - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | FutureChem | 30 | 2020-10-14 | 2022-10-20 |
Prostatic Neoplasms (6) · Genital Diseases (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Injections (1) · Single Person (1)
South Korea (5) · United States (2)
Ji Youl Lee (2) · Ji Youl Lee, Ph.D (2) · Arif Hussain, MD (1) · Jae Young Joung, Ph.D (1) · Steven Rowe, M.D., Ph.D. (1)